Search

Find out what Memorial Sloan Kettering experts recommend when it comes to marijuana, CBD, and other forms of cannabis for cancer.

… Tuesday, June 15, 2021 New York State is the latest to legalize the recreational use of marijuana for adults. We asked Nirupa Raghunathan , an integrative medicine doctor at Memorial Sloan Kettering, and pharmacist Jason Hou, who manages MSK’s About Herbs database, to share what people with cancer should

The new cells, which the scientists have dubbed killer innate-like T cells, differ in several notable ways from the conventional target of many immunotherapies.

… Wednesday, April 20, 2022 Despite the success of immunotherapy in helping many people with cancer, the majority of patients still do not respond to these treatments. There is need for continued research. On April 20, 2022, researchers at the Sloan Kettering Institute reported in the journal Nature that

… Tuesday, July 1, 2014 Physician-scientist Ingo Mellinghoff has been designated the incumbent of the Evnin Family Chair in Neuro-Oncology. Established through the generosity of Dr. Tony Evnin, a general partner of venture capital firm Venrock and a member of Memorial Sloan Kettering’s Boards of Overseers

Across the United States, there is a disparity in the rate of people who are candidates for a partial nephrectomy — those with small renal tumors — and those who actually have the procedure.

… Wednesday, April 18, 2018 Across the United States, there is a disparity in the rate of people who are candidates for a partial nephrectomy — those with small renal tumors — and those who actually have the procedure. Research shows that this is mainly because the operation is challenging and associated

Researchers identify a biomarker that could predict which lung cancer patients will respond to chemotherapy.

… Tuesday, October 26, 2021 Lung adenocarcinoma, the most common form of  lung cancer  in the United States, can be difficult to cure unless diagnosed at an early stage. Surgery is effective at removing early-stage tumors, but more than half of patients with stage 2 or 3 disease have a recurrence of their

New MSK research uses cryo-electron microscopy to shed new light on the ubiquitin; could help predict the risk of blood clots in cancer patients; reveals why micronuclei burst, accelerating aggressive cancers; and surveys healthcare providers about the benefits and risks of commercial genetic testing.

… Tuesday, September 3, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) uses cryo-electron microscopy to shed new light on the ubiquitin; could help predict the risk of blood clots in cancer patients; reveals why micronuclei burst, accelerating aggressive cancers; and surveys healthcare

… Tuesday, July 1, 2014 Neurosurgeon Mark Bilsky , received the Willet F. Whitmore Award for Clinical Excellence at the 2014 Academic Convocation ceremony and Commencement for students from the Louis V. Gerstner Graduate School of Biomedical Sciences. The annual award is presented to a clinician whose

Cancer is tough, no matter the age. But adolescents and young adults with cancer face a whole host of unique challenges, including delayed diagnoses. MSK created an Adolescent and Young Adult (AYA at MSK) program which unites experts across 16 specialties.

… Thursday, September 17, 2020 Cancer is tough, no matter the age. But adolescents and young adults with cancer face a whole host of unique challenges, including delayed diagnoses. For years, MSK has worked to close the gap between pediatric and adult patients and to improve the experience for people in

Childhood leukemia expert Melvyn Greaves received The Society of Memorial Sloan Kettering Prize at the 2018 Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) commencement.

… Thursday, June 7, 2018 Summary Childhood leukemia expert Melvyn Greaves received The Society of Memorial Sloan Kettering Prize at the 2018 Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) commencement. At this year’s Gerstner Sloan Kettering Graduate School of Biomedical Sciences

Learn about a three-drug treatment that has been shown to extend survival for ER+, HER2- breast cancers.

… Saturday, May 31, 2025 Most breast cancers are estrogen receptor (ER) positive, meaning they depend on estrogen to survive and grow. Doctors treat these cancers with drugs that cut off their fuel supply, an approach called  endocrine therapy . Unfortunately, ER-positive breast cancers often become resistant